Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Kartik Sehgal, M.B.,B.S.

Title
Institution
Department
Address
Phone
Fax
Profile Picture

Biography
Dana-Farber Cancer Institute, Boston, MA07/2020Research Fellow, Barbie Lab
Beth Israel Deaconess Medical Center, Boston, MA06/2020Hematology-Oncology Fellowship
Yale-New Haven Hospital, New Haven, CT06/2017Internal Medicine Residency
Yale University, New Haven, CT06/2014Postdoctoral Associate, Dhodapkar Lab
All India Institute of Medical Sciences, New Delhi, India12/2010Medical School

Overview

Featured Content

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, Bikdeli B, Ahluwalia N, Ausiello JC, Wan EY, Freedberg DE, Kirtane AJ, Parikh SA, Maurer MS, Nordvig AS, Accili D, Bathon JM, Mohan S, Bauer KA, Leon MB, Krumholz HM, Uriel N, Mehra MR, Elkind MSV, Stone GW, Schwartz A, Ho DD, Bilezikian JP, Landry DW. Extrapulmonary manifestations of COVID-19. Nat Med. 2020 07; 26(7):1017-1032. PMID: 32651579.
    Citations:    
  2. Sehgal K, Costa DB, Rangachari D. Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic? Front Oncol. 2020; 10:1193. PMID: 32714874.
    Citations:    
  3. Sehgal K, Varkaris A, Viray H, VanderLaan PA, Rangachari D, Costa DB. Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized? J Immunother Cancer. 2020 06; 8(1). PMID: 32581048.
    Citations:    
  4. Sehgal K, Piper-Vallillo AJ, Viray H, Khan AM, Rangachari D, Costa DB. Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond? Precis Cancer Med. 2020 Jun; 3. PMID: 32776005.
    Citations:    
  5. Sehgal K, Bulumulle A, Brody H, Gill RR, Macherla S, Qilleri A, McDonald DC, Cherry CR, Shea M, Huberman MS, VanderLaan PA, Weiss GJ, Walker PR, Costa DB, Rangachari D. Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non-small-cell Lung Cancer. Clin Lung Cancer. 2020 Jun 05. PMID: 32653295.
    Citations:    
  6. Bikdeli B, Madhavan MV, Gupta A, Jimenez D, Burton JR, Der Nigoghossian C, Chuich T, Nouri SN, Dreyfus I, Driggin E, Sethi S, Sehgal K, Chatterjee S, Ageno W, Madjid M, Guo Y, Tang LV, Hu Y, Bertoletti L, Giri J, Cushman M, Quéré I, Dimakakos EP, Gibson CM, Lippi G, Favaloro EJ, Fareed J, Tafur AJ, Francese DP, Batra J, Falanga A, Clerkin KJ, Uriel N, Kirtane A, McLintock C, Hunt BJ, Spyropoulos AC, Barnes GD, Eikelboom JW, Weinberg I, Schulman S, Carrier M, Piazza G, Beckman JA, Leon MB, Stone GW, Rosenkranz S, Goldhaber SZ, Parikh SA, Monreal M, Krumholz HM, Konstantinides SV, Weitz JI, Lip GYH. Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. Thromb Haemost. 2020 Jul; 120(7):1004-1024. PMID: 32473596.
    Citations:    
  7. Sehgal K, Barbie DA. Clonal Selection Drives NF-?B Activation in Recurrent Nasopharyngeal Carcinoma. Cancer Res. 2019 12 01; 79(23):5915-5916. PMID: 31791959.
    Citations:    
  8. Piper AJ, Sehgal K, Costa DB, Rangachari D. Can PD-L1 tumor proportion score be used as the key to unlocking the KEYNOTE studies of pembrolizumab in advanced lung cancer? Transl Lung Cancer Res. 2019 Oct; 8(5):715-722. PMID: 31737509.
    Citations:    
  9. Varkaris A, Sehgal K, Rangachari D, Costa DB. Complete and Sustained Response of Brain Metastases to Programmed Death 1 Antibody Monotherapy in Treatment-naive Programmed Death Ligand 1-Positive Lung Cancer. J Thorac Oncol. 2019 02; 14(2):e34-e36. PMID: 30683297.
    Citations:    Fields:    
  10. Sehgal K, Patell R, Rangachari D, Costa DB. Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors. Transl Cancer Res. 2018 Aug; 7(Suppl 7):S779-S786. PMID: 30327756.
    Citations:    
  11. Sehgal K, Peters MLB, VanderLaan PA, Rangachari D, Kobayashi SS, Costa DB. Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer. J Thorac Oncol. 2019 01; 14(1):e1-e3. PMID: 29981924.
    Citations:    Fields:    
  12. Ostios-Garcia L, Faig J, Leonardi GC, Adeni AE, Subegdjo SJ, Lydon CA, Rangachari D, Huberman MS, Sehgal K, Shea M, VanderLaan PA, Cheng MP, Marty FM, Hammond SP, Costa DB, Awad MM. Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer. J Thorac Oncol. 2018 07; 13(7):1037-1042. PMID: 29631035.
    Citations: 2     Fields:    
  13. Sehgal K, Das R, Zhang L, Verma R, Deng Y, Kocoglu M, Vasquez J, Koduru S, Ren Y, Wang M, Couto S, Breider M, Hansel D, Seropian S, Cooper D, Thakurta A, Yao X, Dhodapkar KM, Dhodapkar MV. Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets. Blood. 2015 Jun 25; 125(26):4042-51. PMID: 25869284.
    Citations: 21     Fields:    Translation:HumansCellsCTClinical Trials
  14. Sehgal K, Ragheb R, Fahmy TM, Dhodapkar MV, Dhodapkar KM. Nanoparticle-mediated combinatorial targeting of multiple human dendritic cell (DC) subsets leads to enhanced T cell activation via IL-15-dependent DC crosstalk. J Immunol. 2014 Sep 01; 193(5):2297-305. PMID: 25080481.
    Citations: 14     Fields:    Translation:HumansCells
  15. Sehgal K, Dhodapkar KM, Dhodapkar MV. Targeting human dendritic cells in situ to improve vaccines. Immunol Lett. 2014 Nov; 162(1 Pt A):59-67. PMID: 25072116.
    Citations: 12     Fields:    Translation:HumansAnimalsCells
  16. Sehgal K, Guo X, Koduru S, Shah A, Lin A, Yan X, Dhodapkar KM. Plasmacytoid dendritic cells, interferon signaling, and Fc?R contribute to pathogenesis and therapeutic response in childhood immune thrombocytopenia. Sci Transl Med. 2013 Jul 10; 5(193):193ra89. PMID: 23843450.
    Citations: 9     Fields:    Translation:HumansCells
  17. van Vledder MG, Assumpcao L, Munireddy S, Sehgal K, Boctor EM, Choti MA. Development of hepatic pseudotumors for image-guided interventional and surgical research in a large animal model. J Vasc Interv Radiol. 2011 Oct; 22(10):1452-6. PMID: 21703871.
    Citations:    Fields:    Translation:Animals
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Sehgal's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (98)
Explore
_
Co-Authors (25)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.